News
Public · Published
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
Trevi Therapeutics announced that CEO Jennifer Good and CFO David Hastings will take part in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET, and will also hold investor meetings.
Published:
Updated:
What happened
Trevi Therapeutics announced that CEO Jennifer Good and CFO David Hastings will take part in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET, and will also hold investor meetings.
Confirmed
Global impact / market context
Investor meetings give a small clinical-stage drug developer a chance to explain its experimental cough therapy to healthcare investors, which can influence how easily the company raises money and how its shares are valued.
Analyst inference
Trevi has no approved product and is testing Haduvio, an oral extended-release nalbuphine, in chronic cough linked to lung disease. Conference appearances by management are routine for such companies seeking investor attention.
Analyst inference
What to watch
- The fireside chat is scheduled for Wednesday, November 11, at 10:00 a.m. ET, and the conference runs November 10-12 in New York, where management will also meet investors. Confirmed
- Watch whether management uses the meetings to discuss plans for raising new capital, since the company is still developing Haduvio and may need more cash. Proposed
- Listen for updates on Haduvio trial progress and any change in development timelines, because delays or setbacks could raise the company's costs and its need to raise borrowed or investor money. Analyst inference